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ABSTRACT
Objective: This study aimed to monitor the side effects of patients who received antiretroviral medications in a subdistrict of West Jakarta in 2017.
Methods: Descriptive research was performed using data collected prospectively from patients who met our inclusion criteria (total sampling). 
Primary data were obtained from interviews, and secondary data were obtained from medical and prescription records. The Naranjo algorithm was 
used to classify side effects.
Results: The side effects experienced by patients in this study fell into probable (45.45%) and possible (36.36%) categories. However, age (p=0.379), 
gender (p=1), and length of treatment (p=0.07) did not significantly affect the occurrence of side effects.
Conclusion: Monitoring the side effects of antiretroviral medicine is necessary to prevent serious and rare side effects. The occurrence of side effects, 
whether they have an established causal relationship or not, could be prevented by appropriate monitoring.
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INTRODUCTION
Acquired immunodeficiency syndrome (AIDS) is caused by infection with 
the human immunodeficiency virus (HIV). This retrovirus infects the body 
and compromises the function of the immune system. As the infection 
progresses, the body’s immune system is weakened, and the sufferer 
becomes more prone to infection [1]. The World Health Organization 
reported that there were 36.7 million people worldwide with HIV in 2015 
and that 2.1 million of these had been newly detected that year [2]. In 
Indonesia, based on a report from information system HIV/AIDS, there 
were 7146 people with HIV in 2016, of which 4333 were male and 2813 
were female. The highest risk for HIV transmission in Indonesia between 
2010 and 2016 was from sexual intercourse (67,734 people) [3].
To date, no medications have been developed that can kill HIV, but 
highly active antiretroviral therapy, which involves combining drugs 
from several classes, can be used to inhibit HIV replication and slow 
disease progression [4]. Antiretrovirals help to decrease the risk of 
HIV transmission, limit severe opportunistic infection, improve quality 
of life, and decrease the total viral count in the blood to undetectable 
levels. Four antiretroviral classes, grouped by their mechanism of 
action, are combined to achieve these therapeutic aims in double or 
triple therapy [5]. The first group is the nucleoside reverse transcriptase 
inhibitors, which comprises zidovudine, tenofovir, stavudine, abacavir, 
and lamivudine. The second group comprises the non-nucleoside 
reverse transcriptase inhibitors such as nevirapine and efavirenz. The 
third group comprises lopinavir, a protease inhibitor, and the fourth 
group comprises raltegravir, an integrase strand transfer inhibitor [6].
Despite the efficacy of antiretroviral therapy, around 25% of the sufferers 
stop therapy in the first 8 months because of treatment failure, non-
compliance, and side effects [7]. The latter can be affected by gender, age, 
and the duration of drug use. Females tend to suffer from side effects due 
to the effects of hormonal changes during the menstrual cycle on drug 
metabolism [8]. Based on research in India, the greatest frequency of 
side effects occurred in the patients aged 41–50 years (68.8%), followed 
by those aged 31–40 years (53.08%) [9]. The possibility of side effects 
because of drug toxicity increases the longer patients who are treated 
with a given medication [10]. Drug side effects, including serious, rare, 
and previously unknown events, can be prevented if proper monitoring 
is done by medical professionals. The Indonesia Ministry of Health 
recommends monitoring for the side effect to improve patient compliance, 
using the Naranjo algorithm to assess this outcome quantitatively [11].
The Kembangan Subdistrict Health Centers, West Jakarta, are public 
health facilities that provide antiretroviral therapy. However, we have 
no reports about the side effect of the antiretroviral drug usage in 
these facilities. A pharmacy standardization service is available in this 
area [11], so we considered that their data could be used to investigate 
side effect rates from antiretroviral drugs in West Jakarta.
METHODS
We used an analytic descriptive research design to investigate 
the monitoring of side effects in patients receiving antiretroviral 
medications in a subdistrict of West Jakarta between March and May, 
inclusive, 2017. First, descriptive data were collected, before those data 
were analyzed to identify relationships between side effects and factors 
such as age, gender, and duration of therapy. The data collection was 
done prospectively [12]. We included patients with HIV/AIDS, who were 
registered in facilities in Kembangan, who consented to become research 
subjects, and who had received highly active antiretroviral therapy for 
at least 7 days. Patients were excluded if they had a comorbid or other 
health disorder, a history of side effects because of antiretroviral therapy, 
and a current opportunistic infection. Data were collected from primary 
interview data and secondary data from medical and prescription 
records. Analyses were then done using IBM SPSS, version 23 for Mac. 
The sample collection technique was total sampling.
RESULTS
In total, we identified 25 patients who received antiretroviral therapy 
in the participating facilities in West Jakarta during the study period; 
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of these, 23 met the inclusion criteria, and two were excluded because 
they did not consent to participate. One of the patients died during the 
study so was excluded because the follow-up was not possible. The final 
cohort comprised 22 patients, and their characteristics are summarized 
in Table 1.
Details regarding their experience of side effects are summarized in 
Tables 2 and 3. Next, we analyzed the relationship between side effects 
and age, gender, or duration of therapy affected drug usage (Tables 4-6). 
As shown in Table 4, there was no relationship between age and side 
effects on antiretroviral drug usage (p=0.379; Chi-square test). Table 5 
shows that there was also no relationship between gender and side 
effects on antiretroviral drug usage (p=1.00, Chi-square test). Similarly, 
there was no significant relationship between the drug usage duration 
and side effects on retroviral drug usage, though this did approach the 
significance threshold of 0.05 (p=0.070; Mann–Whitney U-test).
DISCUSSION
Patient characteristic
Based on a report of the Centers for Disease Control and Prevention 
(CDC), the two age ranges with the highest HIV infection rates in 2015 
in the United States were 20–24 years (n=7084) and 25–29 years 
(n=7510). These were followed by the age of 35–39 years, indicating 
that late adolescence to middle-age has the highest HIV infection 
rates [13]. Our results were consistent with these data reported by 
the CDC. Similarly, we showed that more males (59.09%) than females 
(40.91%) used antiretroviral drugs, which was also consistent with the 
finding by the CDC that males were more prone to infection. This may 
be related to males being more likely to engage in higher risk behaviors, 
including homosexual and heterosexual intercourse and non-sterile 
syringe use [13].
In this study, tenofovir, lamivudine, and efavirenz were the most 
frequently used combination (n=15). This is a first-line option in 
the Indonesia Ministry of Health guidance. The next most frequent 
combination was tenofovir, lamivudine, and nevirapine (n=3), which 
were given to patients who experienced intense side effects with 
efavirenz. This is an appropriate alternative regimen in Indonesia [5]. 
Another three patients used zidovudine, lamivudine, and nevirapine. 
Beyond these, one patient used dual therapy with tenofovir and 
efavirenz, but the reason for omitting lamivudine was not specified, and 
one other patient used second-line options (lopinavir and ritonavir). 
The reason for using these latter agents was drug discontinuation due 
to intense side effects experienced with the first-line combination of 
tenofovir, zidovudine, and efavirenz.
In total, eight patients in this study had used antiretroviral drugs for 
4 weeks–5 months, another eight had used them for 6–12 months, and 
six had used them for >1 year (the usage range was 1 month–10 year). 
Antiretrovirals are to be used for life, so the duration of usage in this 
research referred to the time of the drug usage since the 1st time the 
patient received the drug to the last month of side effect monitoring 
by the research. Thus, unless stated otherwise, patients would be still 
using a given antiretroviral after the researcher stopped.
Side effects
The scores of the Naranjo algorithm indicated that most side effects 
probably happened because of the antiretroviral drug use. However, 
four of the 22 participants did not suffer from side effects during the 
monitoring period (range, 1–12 months; Table 2). The side effects 
experienced by patients are summarized in Table 3 based on the 
Table 1: Patient characteristics
Category Number n=22 (%)
Age
Late adolescent 7 (31.82)
Early adult 9 (40.91)











4 weeks–5 months 8 (36.36)
>5–12 months 8 (36.36)
>1 year 6 (27.27)
Table 2: The classification of side effects by Naranjo algorithm 
result
Category Total patients n=22 (%)
Probable 10 (45.45)
Possible 8 (36.36)
Table 3: The Incidence of side effect by drug combination
Antiretroviral combination Side Effect Incidence Total





Central nervous system disturbance 7




Lamivudine+zidovudine+nevirapine Nausea 2 5
Skin rash 2
Headache 1
Tenofovir+efavirenz Skin rash 1 2
Headache 1
Lopinavir+ritonavir Skin rash 1 2
Nausea 1
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antiretroviral combination. As shown, nausea, vomiting, skin rash, 
and headache were universal side effects, and patients often suffered 
all of these (e.g., interview revealed that a patient could suffer nausea, 
followed by vomiting and headache). Nausea and vomiting can be treated 
pharmacologically (e.g., antiemetics) and non-pharmacologically 
(e.g., counseling about nutrition), making their identification relevant. 
It seemed that most common side effects were only experienced early 
during therapy.
The most common side effect was central nervous system disturbance, 
and this included nightmares, hallucinations, “float-like” flying 
sensation, and conscious dreams. These side effects were probably due 
to efavirenz [14] and occurred in seven patients receiving lamivudine, 
tenofovir, and efavirenz. Our findings are supported by the research 
of Jain et al. in India [15]. They showed that the most commonly used 
therapeutic combination was lamivudine, tenofovir, and efavirenz (83 of 
100 patients), but that 81 experienced side effects due to efavirenz [15]. 
Although the side effects of efavirenz commonly disappeared after 
6–10 weeks, they could persist long-term in some patients [16].
The most serious side effect of all antiretrovirals is hepatotoxicity. In 
addition, nucleoside reverse transcriptase inhibitors may cause lactic 
acidosis, kidney failure, and anemia, while protease inhibitors may 
cause the Stevens–Johnson syndrome. Lactic acidosis could happen 
because of mitochondrial toxicity, with gamma polymerase DNA being 
inhibited by the nucleoside reverse transcriptase inhibitors [16], 
but there was no evidence of this side effect in our cohort (Table 3). 
However, the medical records only covered laboratory results for serum 
glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, and 
urea, as well as the creatinine clearance. We were still able to conclude 
that the hepatic and kidney functions of all patients were normal.
Relationship between age and side effects
There was no relation between age and side effects in terms of 
antiretroviral drug usage (Table 4, p=0.379). Malalur et al. found 
that adults had a higher prevalence of side effects because of 
pharmacokinetic factors such as absorption, distribution, metabolism, 
and elimination [17]. In adults, gastric acid levels could be increased 
and stomach clearance could be delayed. Moreover, decreased efficiency 
of the digestive tract could lead to a decrease in the total amount of drug 
absorbed, and a disturbed water content of the body could increase the 
relative concentration of water-soluble drugs in the plasma. Hepatic 
and kidney function also decrease as we age, so impaired metabolism 
and excretion could also be factors [18-20]. Similar to our result, 
however, other research has shown that age did not influence side effect 
rates. The potential for side effects to increase with age could, therefore, 
be caused by unsuitable dosages and routes of administration for the 
patient’s age; however, those factors are accounted for drug Category A 
and can be prevented [21]. The lack of a relationship between age and 
side effects in this research could be caused by the small sample size.
Relationship between gender and side effects
As with age, there was no relationship between gender and side effects 
in terms of antiretroviral drug use in our cohort (Table 5, p=1.00). Other 
research has indicated that more males than females experience side 
effects when taking antiretroviral drugs. Indeed, it has been stated 
that the mean difference in weight and body mass index between 
males and females could account for different prevalence rates of 
side effects [8]. Furthermore, Floridia et al. reported that differences 
in side effect frequency could be caused by differences in hormonal 
factors, pharmacokinetic factors, compliance, and acceptance of side 
effects between the sexes [22,23]. Our failure to show a difference 
was probably a consequence of the small sample size. Further study is 
needed to clarify the relationship between gender and side effects.
Relationship between the duration of drug usage and side effects
Finally, there was no significant relationship between the duration of 
drug usage and side effects on the use of antiretroviral drugs (Table 6), 
though this did approach the 2-tailed significance threshold of 0.05 
(i.e., p=0.070). Of the eight patients who had taken antiretroviral drugs 
for 4 weeks–5 months, a total of six (75%) patients experienced side 
effects. Among the eight patients who had taken antiretrovirals for 
6–12 months, another six (75%) patients experienced side effects. 
However, of the six patients who had taken antiretrovirals for >1 year, 
all experienced side effects. Interviewing the patients revealed that 
the most intense side effects happened early during therapy (typically 
within the first 6 months), possible because of intolerance while the 
body became used to the drug. Careful monitoring for drug side effects 
during this early period could prevent drug discontinuation in some 
patients [24]. By contrast, monitoring in the long-term is important 
to identify toxicity and potentially serious side effects, such as kidney 
failure, bone marrow suppression, and anemia [10].
Table 4: Relationship between age and side effects on drug usage
Category Total patients (n=22) Side effects Percentage (%) p
Age 0.379
Early adolescent (12–16 years) 0 0 0
Late adolescent (>16–25 years) 7 5 71.4
Early adult (>25–35 years) 9 7 77.8
Late adult (>35–45 years) 6 6 100
Table 5: Relationship between gender and side effects on drug usage
Category Total patients (n=22) Side effect Percentage (%) p
Age
Female 7 6 85.7 1.000
Male 15 12 80
Table 6: Relationship between drug usage duration and side effects on drug usage
Category Total patients (n=22) Side effect Percentage (%) p
Usage duration 0.070
>3 weeks–5 months 8 6 75
>5–12 months 8 6 75
>1 year 6 6 100
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CONCLUSION
In West Jakarta in 2017, the most common first-line antiretroviral 
combination was lamivudine, tenofovir, and efavirenz (68.18%), and 
there were 28 reports of side effects with antiretroviral usage, typically 
due to this combination. However, there was no significant relationship 
between age, gender, or duration of drug usage and side effects.
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